Eiger BioPharmaceuticals Inc.

Eiger BioPharmaceuticals Inc is a clinical stage biopharmaceutical company. It is focused on bringing to market novel product candidates for the treatment of orphan diseases. The company’s lead program is Lonafarnib, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. The company’s pipeline includes five Phase 2 development programs addressing four distinct orphan diseases. The pipeline includes lonafarnib for Hepatitis Delta Virus, or HDV, PEG-interferon lambda-1a (lambda) for HDV, exendin 9-39 for Post-Bariatric Hypoglycemia, or PBH and ubenimex for Pulmonary Arterial Hypertension, or PAH and lymphedema.